BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18619542)

  • 1. An investigation into CAG repeat length variation and N/C terminal interactions in the T877A mutant androgen receptor found in prostate cancer.
    Southwell J; Chowdhury SF; Gottlieb B; Beitel LK; Lumbroso R; Purisima EO; Trifiro M
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):138-46. PubMed ID: 18619542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor.
    Dubbink HJ; Hersmus R; Verma CS; van der Korput HA; Berrevoets CA; van Tol J; Ziel-van der Made AC; Brinkmann AO; Pike AC; Trapman J
    Mol Endocrinol; 2004 Sep; 18(9):2132-50. PubMed ID: 15178743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.
    Dubbink HJ; Hersmus R; Pike AC; Molier M; Brinkmann AO; Jenster G; Trapman J
    Mol Endocrinol; 2006 Aug; 20(8):1742-55. PubMed ID: 16627595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions.
    Duff J; McEwan IJ
    Mol Endocrinol; 2005 Dec; 19(12):2943-54. PubMed ID: 16081517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.
    Buchanan G; Need EF; Barrett JM; Bianco-Miotto T; Thompson VC; Butler LM; Marshall VR; Tilley WD; Coetzee GA
    Mol Cell Endocrinol; 2011 Aug; 342(1-2):20-31. PubMed ID: 21664238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions.
    Yang CS; Xin HW; Kelley JB; Spencer A; Brautigan DL; Paschal BM
    Mol Cell Biol; 2007 May; 27(9):3390-404. PubMed ID: 17325038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2).
    Lim J; Ghadessy FJ; Abdullah AA; Pinsky L; Trifiro M; Yong EL
    Mol Endocrinol; 2000 Aug; 14(8):1187-97. PubMed ID: 10935543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a short CAG (glutamine) repeat on human androgen receptor function.
    Ding D; Xu L; Menon M; Reddy GP; Barrack ER
    Prostate; 2004 Jan; 58(1):23-32. PubMed ID: 14673949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2).
    Berrevoets CA; Doesburg P; Steketee K; Trapman J; Brinkmann AO
    Mol Endocrinol; 1998 Aug; 12(8):1172-83. PubMed ID: 9717843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer.
    Steketee K; Timmerman L; Ziel-van der Made AC; Doesburg P; Brinkmann AO; Trapman J
    Int J Cancer; 2002 Jul; 100(3):309-17. PubMed ID: 12115546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China.
    Hsing AW; Gao YT; Wu G; Wang X; Deng J; Chen YL; Sesterhenn IA; Mostofi FK; Benichou J; Chang C
    Cancer Res; 2000 Sep; 60(18):5111-6. PubMed ID: 11016637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural features discriminate androgen receptor N/C terminal and coactivator interactions.
    Askew EB; Minges JT; Hnat AT; Wilson EM
    Mol Cell Endocrinol; 2012 Jan; 348(2):403-10. PubMed ID: 21664945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor (AR) NH2- and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth.
    Hsu CL; Chen YL; Ting HJ; Lin WJ; Yang Z; Zhang Y; Wang L; Wu CT; Chang HC; Yeh S; Pimplikar SW; Chang C
    Mol Endocrinol; 2005 Feb; 19(2):350-61. PubMed ID: 15514032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collocation of androgen receptor gene mutations in prostate cancer.
    Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
    Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Domain interactions between coregulator ARA(70) and the androgen receptor (AR).
    Zhou ZX; He B; Hall SH; Wilson EM; French FS
    Mol Endocrinol; 2002 Feb; 16(2):287-300. PubMed ID: 11818501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells.
    Masiello D; Chen SY; Xu Y; Verhoeven MC; Choi E; Hollenberg AN; Balk SP
    Mol Endocrinol; 2004 Oct; 18(10):2388-401. PubMed ID: 15256534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action.
    Ding D; Xu L; Menon M; Reddy GP; Barrack ER
    Prostate; 2005 Feb; 62(2):133-9. PubMed ID: 15389799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.
    Sack JS; Kish KF; Wang C; Attar RM; Kiefer SE; An Y; Wu GY; Scheffler JE; Salvati ME; Krystek SR; Weinmann R; Einspahr HM
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4904-9. PubMed ID: 11320241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.
    Askew EB; Gampe RT; Stanley TB; Faggart JL; Wilson EM
    J Biol Chem; 2007 Aug; 282(35):25801-16. PubMed ID: 17591767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.